

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Ortho Regenerative Technologies Inc. (the "Issuer")**

Trading Symbol: **ORTH**

Number of Outstanding Listed Securities: **24,712,424**

Date: **January 8th, 2019**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Corporation continues to implement operational initiatives to meet its business objectives including the implementation of its pre-clinical development plan and prosecution for its four patent families.

2. Provide a general overview and discussion of the activities of management.

In the period, Management's primary focus was to (i) continue to raise capital (ii) pursue the activities relating to our pre-clinical and clinical development path and scale-up of our manufacturing process including the completion of the Pre-Submission package for the United States Food and Drug Administration (iii) initiate

formal discussions with potential sub-contractants for our phase I/II human trial, (iv) initiate planning activities for proof-of-concept studies relating to the use of our Ortho-M products for the treatment/repair of meniscus tear.

The company announced that its recently completed study has been chosen by a peer reviewed panel as worthy of a podium presentation at the 2019 ICORS (International Combined meeting of Orthopaedic Research Societies) congress in June. ICORS attracts Orthopaedic surgeons, sports medicine specialists, physicians and research scientists from around the globe and is focused on how new discoveries translate into improved clinical care. The podium presentation will feature the study titled "Freeze-dried chitosan solubilized in platelet-rich plasma in a sheep model of rotator cuff repair"

The company also announced that it had submitted a formal Pre-Submission package to the FDA seeking guidance after our recent data showed statistically significant results in as little as 3 months. The package included data from all our studies and highlighted that Ortho-R has shown structural improvements at 6 months and as a second clinical benefit has showed improved speed of healing as evidenced by our 3-month data.

Over the same time period our Intellectual Property assets continued to grow with progress on multiple patent files as well as another European patent issuing in Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Switzerland & Liechtenstein, and the United Kingdom.

As part of the evolving scientific validation of our technology, a recent manuscript was selected for publication in an upcoming issue of the Journal of Biomaterials which is expected to be published in the first months of 2019.

Finally, our technology transfer to production and scale-up has progressed through a critical milestone with our first finished product lots in the process of being completed

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Nothing applicable during the period.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Nothing applicable during the period.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Nothing applicable during the period.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Nothing applicable during the period.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
Nothing applicable during the period.
8. Describe the acquisition of new customers or loss of customers.
Nothing applicable during the period.
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
Nothing applicable during the period.
10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.
Nothing applicable during the period.
11. Report on any labour disputes and resolutions of those disputes if applicable.
Nothing applicable during the period.
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
Nothing applicable during the period.
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
The corporation has secured two term loans to finance its 2017-2018 and 2019 SR&ED tax credits. The gross amounts received under this facility totalled \$388,600. The terms of these SR&ED tax credit financings are respectively for six and twelve months calculated as of the date of the loan disbursements, which was December 21st, 2018.
14. Provide details of any securities issued and options or warrants granted.
Nothing applicable during the period
15. Provide details of any loans to or by Related Persons.
No new loans with related parties in the current period
16. Provide details of any changes in directors, officers or committee members.
Nothing applicable during the period
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None in the current period.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: January 8th, 2019

Ortho Regenerative Technologies Inc.
/s/ Luc Mainville
Senior VP & Chief Financial Officer
Official Capacity

Issuer Details	For Month End	Date of Report
Name of Issuer Ortho Regenerative Technologies Inc.	December 2018	YY/MM/D 2019/01/08
Issuer Address 16667, Boul. Hymus,		
City/Province/Postal Code Kirkland, Quebec, H9H 4R9	Issuer Fax No. 514.694.0443	Issuer Telephone No. 514.694.0865
Contact Name Luc Mainville	Contact Position Sr. VP & CFO	Contact Telephone No. (514) 693-8854
Contact Email Address mainville@orthorti.com	Web Site Address www.orthorti.com	